For Insurers

COST EFFECTIVENESS = CLINICAL BENEFIT + COST SAVINGS
The cost of treating cancer was found to be the largest contributor to
increased costs associated with screening with HPV-Alone*1

Why mRNA?

mRNA-based HPV screening assess the presence and activity of a high-risk HPV infection,2,3 while DNA-based HPV screening assesses the presence of a high-risk HPV infection.



24% Reduction in false positives4

mRNA-based screening provides the same excellent sensitivity as DNA-based screening, but offers increased specificity, which results in a 24% reduction in false positives.4 Combined with better sensitivity of the image-guided Pap test, this was the most influential factor in the incremental difference in cost savings in a recent clinical-economic modeling study.1

 

The increased rate of false-positive results with DNA-based HPV testing could lead to5:

 

Unnecessary procedures

Unnecessary procedures
and overtreatment

Increased anxiety

Increased anxiety and
emotional burden

Higher Health

Higher health
care costs